Cognition Therapeutics to Present at the TD Cowen Health Care Conference
26 févr. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders,...
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
06 févr. 2024 08h47 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that...
Cognition Therapeutics CEO Issues Letter to Shareholders
04 janv. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from Phase 2 SHIMMER trial in mild-to-moderate dementia with Lewy...
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
16 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode:...
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
15 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the...
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
07 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
- Top-line results expected mid 2024 -- Strong physician interest drove SHINE study completion - PURCHASE, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the...
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
02 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
Phase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early stage Alzheimer’s disease START trial; will...
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
27 oct. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the...
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
24 oct. 2023 16h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior...
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
16 oct. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
Cognition Therapeutics announced presentations from studies of CT1812 at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference